Hematology/Oncology

Top Story

Prostate radiotherapy, ADT may extend metastatic prostate cancer survival

August 26, 2016

The addition of prostate radiotherapy to androgen deprivation may prolong survival in men with newly diagnosed metastatic prostate cancer, according to a study published in Journal of Clinical Oncology.

Prostate radiotherapy represents an attractive local treatment strategy for patients with metastatic prostate cancer, given its noninvasive administration and broad patient candidacy, advancements in delivery allowing for an increasingly favorable toxicity profile, the established role of radiotherapy in the management of locally advanced nonmetastatic prostate cancer, and recent associations between radiotherapy and improved survival for men with lymph node–positive prostate cancer,” Chad G. Rusthoven, MD, radiation oncologist and assistant professor of radiation oncology at University of Colorado School of Medicine, and colleagues wrote.

Meeting News Coverage

Study results from ASCO ‘exciting’ for patients with head and neck, lung cancer

August 26, 2016
Several studies of treatment options for cancers previously believed by physicians to be unresponsive to immunotherapy appeared to produce positive data in patients with…
In the Journals

Gene therapy superior to haploidentical HSCT for SCID-X1

August 26, 2016
Gene therapy was associated with faster T-cell reconstitution and a better long-term thymic output than partially matched hematopoietic stem cell transplantation for…
In the Journals Plus

Survivors of Hodgkin lymphoma face high cardiovascular toxicity burden

August 26, 2016
Cardiovascular toxicities occurred more frequently and severely among adult survivors of pediatric, adolescent and young adult Hodgkin lymphoma than in the general…

21st Century Oncology appoints research director

August 26, 2016
Ajay Bhatnagar, MD, MBA, a board-certified radiation oncologist, has been named research director for 21st Century Oncology’s cancer treatment centers in Arizona…
More News Headlines »
CME

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Video
Meeting News Coverage

VIDEO: Neratinib benefits patients with HER-2–negative breast cancer

August 20, 2016
More »
Featured
Discoveries from ASCO 2016: Breast Cancer

Discoveries from ASCO 2016: Breast Cancer

CME

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan